RT期刊论文SR电子T1社会经济偏见哮喘控制和可能的严重哮喘JF欧洲呼吸杂志JO欧元呼吸杂志FD欧洲呼吸学会SP的专家推荐2100741 DO 10.1183 / 13993003.00741-2021 A1哈坎森，谢尔埃里克·朱利叶斯·A1靠山，人Vibeke A1 Suppli188bet官网地址Ulrik，Charlotte YR 2021 UL //www.qdcxjkg.com/content/early/2021/05/06/13993003.00741-2021.Abstract ab背景虽然已经调查了对哮喘控制的社会经济影响，但对其与之关系知之甚少专家对可能的严重哮喘的患者转诊，特别是在公共医疗保健环境中。本研究旨在识别患有吸入皮质类固醇（ICS）治疗的全国性患者哮喘患者疾病控制和哮喘患者患者的社会经济模式。哮喘患者履行以下内容：年龄18-45岁，兑换≥2次判定在2014-18期间，基于丹麦国家寄存器的数据包括在内。可能的严重哮喘定义为GINA 2020步骤4（≥2种疗程的全身类固醇或≥1次住院）或步骤5治疗。作为差距（或）的结果（或）（95％置信区间）。结果60例534名患者（中位数34岁，55％的女性），3275（5.7％）被认为具有可能的严重哮喘，其中61％进行了管理单纯的初级保健。用于可能的严重哮喘的专业管理，随着年龄的增长（或0.66（0.51-0.85）），36-45与18-25岁），男性（或0.75（0.64-0.87）），居住在外面资本区域（或0.70.82））和接受失业或残疾福利或0.75（0.59-0.95））。与患者相比，已完成高等教育增加了专业转诊的几率（或1.28（1.03-1.59））通过基础教育。即使在具有全国可用的自由访问专家护理的环境中结论，患有严重哮喘的大多数患者在初级保健中管理。 Referral of at-risk asthma patients differs across socioeconomic parameters, calling for initiatives to identify and actively refer these patients.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Kohli has nothing to disclose.Conflict of interest: Dr. Håkansson reports personal fees from AstraZeneca, personal fees from Chiesi, personal fees from TEVA, outside the submitted work.Conflict of interest: Dr. Backer reports personal fees from AstraZeneca, personal fees from GSK, personal fees from TEVA, personal fees from Sanofi Genzyme, personal fees from MSD, personal fees from Chiesi, personal fees from Novartis, personal fees from ALK-Abello, personal fees from Mundipharma , personal fees from Boehringer-Ingelheim, from Pharmaxis, outside the submitted work.Conflict of interest: Dr. Suppli Ulrik reports personal fees from AstraZeneca, personal fees from GSK, personal fees from TEVA, personal fees from Sanofi Genzyme, personal fees from Boehringer-Ingelheim, personal fees from Orion Pharma, personal fees from Novartis, personal fees from ALK-Abello, personal fees from Mundipharma , personal fees from Actelion, outside the submitted work;.